| [1] |
Cohn JN,Goldstein SO,Greenberg BH,et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure[J].N Engl J Med,1999,339(25):1810-1816.
|
| [2] |
Tang CL,Xie DS,Feng BN.A novel therapeutic approach for systolic heart failure:cardiac myosin activators[J].Chin J New Drugs(中国新药杂志),2013,22(16):1916-1920.
|
| [3] |
Tamargo J, López-Sendón J. Novel therapeutic targets for the treatment of heart failure[J].Nat Rev Drug Discov,2011,10(7):536-555.
|
| [4] |
Spirito P,Seidman CE,McKenna WJ,et al. The management of hypertrophic cardiomyopathy[J].N Engl J Med,1997,336(11):775-785.
|
| [5] |
Packer M,Carver JR,Rodeheffer RJ,et al. Effect of oral milrinone on mortality in severe chronic heart failure[J].N Engl J Med,1991,325(21):1468-1475.
|
| [6] |
Malik FI,Morgan BP.Cardiac myosin activation part 1:from concept to clinic[J].J Mol Cell Cardiol,2011,51(4):454-461.
|
| [7] |
Malik FI,Hartman JJ,Elias KA,et al. Cardiac myosin activation:a potential therapeutic approach for systolic heart failure[J].Science,2011,331(6023):1439-1443.
|
| [8] |
Cleland JG,Teerlink JR,Senior R,et al. The effects of the cardiac myosin activator,omecamtiv mecarbil,on cardiac function in systolic heart failure:a double-blind,placebo-controlled,crossover,dose-ranging phase 2 trial[J].Lancet,2011,378(9792):676-683.
|
| [9] |
Morgan BP,Muci A,Lu PP,et al. Discovery of omecamtiv mecarbil the first,selective,small molecule activator of cardiac Myosin[J].ACS Med Chem Lett,2010,1(9):472-477.
|
| [10] |
Hao AT,Lin F,Greenberg BH.Potential new drug treatments for congestive heart failure[J].Expert Opin Investig Drugs,2016,25(7):811-826.
|
| [11] |
Tang CL,Xie DS,Feng BN.Zebrafish as a new model for phenotype-based screening of positive inotropic agents[J].Chem Biol Drug Des,2015,85(3):253-258.
|
| [12] |
Wang GP,Tang CL,Yan GJ,et al.Gene expression profiling of H9c2 cells subjected to H2O2-induced apoptosis with/without AF-HF001[J].Biol Pharm Bull,2016,39(2):207-214.
|
下载:
